Avenue Therapeutics, Inc. (NASDAQ:ATXI) CFO Sells $11,599.20 in Stock

Avenue Therapeutics, Inc. (NASDAQ:ATXI) CFO Joseph Walter Vazzano sold 7,160 shares of the firm’s stock in a transaction that occurred on Wednesday, September 15th. The stock was sold at an average price of $1.62, for a total transaction of $11,599.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of ATXI traded down $0.09 during mid-day trading on Wednesday, reaching $1.64. The company had a trading volume of 705 shares, compared to its average volume of 258,168. The stock has a market cap of $27.47 million, a price-to-earnings ratio of -3.04 and a beta of 0.61. The firm has a fifty day simple moving average of $1.85 and a 200-day simple moving average of $3.74. Avenue Therapeutics, Inc. has a fifty-two week low of $1.53 and a fifty-two week high of $12.21.

Avenue Therapeutics (NASDAQ:ATXI) last announced its quarterly earnings results on Sunday, August 15th. The company reported ($0.06) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.06). On average, equities research analysts expect that Avenue Therapeutics, Inc. will post -0.21 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC acquired a new position in shares of Avenue Therapeutics in the 2nd quarter valued at $183,000. Occudo Quantitative Strategies LP purchased a new position in shares of Avenue Therapeutics in the 2nd quarter valued at $36,000. Goldman Sachs Group Inc. raised its stake in shares of Avenue Therapeutics by 34.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 23,224 shares of the company’s stock valued at $58,000 after acquiring an additional 5,905 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Avenue Therapeutics in the 2nd quarter valued at $197,000. Finally, XTX Topco Ltd purchased a new position in shares of Avenue Therapeutics in the 2nd quarter valued at $27,000. Institutional investors own 6.71% of the company’s stock.

Separately, Zacks Investment Research upgraded shares of Avenue Therapeutics from a “sell” rating to a “hold” rating and set a $1.75 target price on the stock in a research report on Tuesday, August 17th.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain.

Featured Article: What is the accumulation/distribution indicator?

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.